Skip to content

Targeted OXYgen Therapy in Critical Illness

A Randomised Controlled Trial of Targeted Oxygen Therapy in Mechanically Ventilated Critically Ill Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03287466
Acronym
TOXYC
Enrollment
34
Registered
2017-09-19
Start date
2018-01-15
Completion date
2020-02-15
Last updated
2021-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Respiratory Failure

Keywords

oxygen, oxygen saturation, oxygen concentration

Brief summary

The investigators propose to conduct a feasibility, multi-centre, randomised controlled trial of targeted oxygen therapy in adult critically ill patients receiving mechanical ventilation via an endotracheal tube as part of their treatment for respiratory failure. Participants will be allocated to either a normal blood oxygen target group or a lower than normal blood oxygen target group. The primary purpose of the study will be to assess the feasibility of recruiting complex patients who lack capacity into a clinical trial in which oxygenation is being assessed, and that the clinicians responsible for these patients are able to deliver the intervention effectively. The safety of using a lower than normal blood oxygen target will also be assessed and blood samples taken for subsequent investigation of the biological mechanisms underlying the observed changes. Participants will be randomised (1:1) into either an intervention or control group. The intervention in this trial is tightly controlled administration of oxygen to patients to achieve a haemoglobin oxygen saturation (SpO2) of 88-92%. The control group will also have tightly controlled oxygen administration, but to achieve an SpO2 of 96% or above. The target for the control group represents a normal SpO2, whilst that in the intervention group is lower than what is considered to be normal. It should be noted that although lower than normal, this SpO2 is close to what the general public experience when travelling by pressurised aircraft as the fractional inspired oxygen concentration in that situation is only 0.15-0.17 (15-17%). The controlled oxygen administration would commence as soon as possible after admission to the critical care unit and end following removal of the participant's artificial breathing tube. The researchers and clinical team cannot be blinded to treatment allocation, due to the nature of the intervention. Those analysing the data will be blinded to the intervention.

Detailed description

The investigators aim is to determine whether revising standard targets for blood oxygen levels in patients requiring artificial ventilation on a critical care unit is feasible and whether this affects specific blood biomarker levels. Investigators in this area of expertise currently lack the information necessary to determine how much oxygen should be given to adult critically ill patients on a mechanical ventilator to assist their breathing in order to achieve the best clinical outcomes i.e. minimal morbidity and mortality. Excessive oxygen administration (both its concentration and duration) and hyperoxaemia (an excessively high blood oxygen level) are known to be harmful to critically ill patients. The reason for this is that oxygen in high concentration is toxic, because it results in the release of molecules called reactive oxygen species (ROS). ROS lead to a state known as 'oxidative stress', in which cells and tissues are rapidly destroyed by these destructive molecules. The difficulty with treating critically ill patients is that they are usually extremely unwell, requiring artificial ventilation to support their breathing. Unfortunately, these patients appear to be exceptionally prone to the harms of oxidative stress, leading to permanent damage of their lungs. Yet it is precisely this group of patients who require high concentration oxygen to keep their blood oxygen levels within the normal. It has therefore been hypothesised that using lower blood oxygen targets than usual may be beneficial to these patients through the avoidance of excessively high concentrations of oxygen. The investigator proposes that in mechanically ventilated critically ill patients harm (morbidity and mortality) will be reduced by using 'targeted oxygen therapy' (TO2T) to achieve lower blood oxygen levels than normal when compared to standard practice (normal blood oxygen levels). The levels are only moderately lower than normal and well within what most clinicians would consider to be safe in these patients. Prior to any large-scale study, it is important to understand if this approach to managing critically ill patients is feasible. This prospective, dual site randomised controlled trial will therefore establish whether it is possible to conduct a trial in which blood oxygen levels are carefully titrated by the critical care team, to achieve specific targets. Participants will be allocated into one of two groups: i) normal blood oxygen levels, and ii) low blood oxygen levels. For the time that participants are artificially ventilated by a breathing (endotracheal) tube, they will remain in their allocated treatment group. Information will be collected from the patient's charts and records during their stay on the CCU to assess the impact of the treatment. A series of blood samples will also be collected from participants to quantify the degree of oxidative stress through the measurement of several specific biomarkers. A total of 60 patients will be enrolled at two sites. As oxygen is a drug that is administered to almost every patient admitted to a critical care unit (CCU), it is imperative that decisions regarding oxygenation are based upon evidence rather than conjecture. Limited work has been undertaken to date to understand whether lowering blood oxygen levels is achievable in this complex patient group. The information from this study will be used to design a subsequent much larger study to fully evaluate whether TO2T to achieve lower blood oxygen levels saves lives in critically ill patients. If lower blood oxygen levels improve survival in critically ill patients implementation of this intervention could have an immediate and cost-effective impact across the entire National Health Service.

Interventions

DRUGOxygen

targeted oxygen therapy

Sponsors

Royal Free Hospital NHS Foundation Trust
CollaboratorOTHER
University Hospital Southampton NHS Foundation Trust
CollaboratorOTHER
National Institute for Health Research, United Kingdom
CollaboratorOTHER_GOV
Royal Free Charity
CollaboratorUNKNOWN
University College, London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Masking description

Clinicians and other healthcare providers will not be blinded to treatment allocation, nor will the clinical research team. This is because knowing the patient's blood oxygen level is an essential component of the study. Those members of the research team analysing data after the recruitment phase of the study will be blinded to group allocation. Participants will not be blinded but are unlikely to be aware to their allocation due to the severity of their illness.

Intervention model description

feasibility, multi-centre, randomised controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Unplanned admission to a critical care unit * 18 years of age and above (no upper age limit) * Respiratory failure forms part of the admission diagnosis * The patient is mechanically ventilated via an endotracheal tube * The patient is expected to receive mechanical ventilation for \> 24 hours

Exclusion criteria

* Admission following surgery (elective or unplanned) * Those patients expected to die within 24 hours of admission to ICU \* * Pregnant females * Admission post-cardiac arrest * Admission post trauma (including traumatic brain injury) * Known sickle cell trait or disease * Ongoing significant haemorrhage or profound anaemia * Severe peripheral vascular disease * Severe pulmonary hypertension * Other medical conditions where mild hypoxaemia would be contra-indicated \*\*\* * Patients participating in other interventional clinical trials * As determined by the responsible clinical team \*\* As determined by the responsible clinical team and /or research team

Design outcomes

Primary

MeasureTime frameDescription
Feasibility to recruit15 MonthsAbility to recruit

Secondary

MeasureTime frameDescription
Measurement of arterial blood gasesup to 21 daysMeasurement of arterial blood gases
Measurement of oxygen saturationup to 21 daysMeasurement of oxygen saturation
Measurement of fraction of inspired oxygenup to 21 daysMeasurement of fraction of inspired oxygen
Time to extubation / detachment from mechanical ventilationup to 21 daysTime to extubation / detachment from mechanical ventilation
Mechanical ventilation free days on ICUup to 21 daysMechanical ventilation free days on ICU
Measurement of blood pressureup to 21 daysMeasurement of blood pressure
Measurement of heart rateup to 21 daysMeasurement of heart rate
Measurement of cardiac rhythmup to 21 daysMeasurement of cardiac rhythm
Measurement of cardiac output and stroke volume (if measured)up to 21 daysMeasurement of cardiac output and stroke volume (if measured)
Measurement of vasopressor dosesup to 21 daysMeasurement of vasopressor doses
Measurement of inotrope dosesup to 21 daysMeasurement of inotrope doses
Measurement of daily fluid balanceup to 21 daysMeasurement of daily fluid balance
Measurement of inotrope free days on ICUup to 21 daysMeasurement of inotrope free days on ICU
Measurement of vasopressor free days on ICUup to 21 daysMeasurement of vasopressor free days on ICU
Measurement of Ureaup to 21 daysMeasurement of Urea
Measurement of blood clotting valuesup to 21 daysMeasurement of blood clotting values
Measurement of urine outputup to 21 daysMeasurement of urine output
The need for renal replacement therapyup to 21 daysThe need for renal replacement therapy
Renal replacement therapy free days on ICUup to 21 daysRenal replacement therapy free days on ICU
Measurement of transaminasesup to 21 daysMeasurement of transaminases
Measurement of bilirubinup to 21 daysMeasurement of bilirubin
Measurement of blood lactateup to 21 daysMeasurement of blood lactate
Measurement of Troponinup to 21 daysMeasurement of Troponin
Adverse events90 daysAdverse events
SOFA score changeup to 21 daysSequential Organ Failure Assessment (SOFA) score change
APACHE II score changeup to 21 daysAcute Physiology and Chronic Health Evaluation (APACHE) II score change
Length of ICU stayup to 21 daysLength of stay in intensive care unit
Length of hospital stay90 daysLength of hospital stay
Mortality rates90 daysDays alive
Days alive out of Hospital90 daysDays alive out of Hospital
Measurement of creatinineup to 21 daysMeasurement of creatinine

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026